Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Effector Therapeutics
With
Merck KGaA, Darmstadt, Germany
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
ECOG performance status of 0, 1, or 2
Pathologically documented diagnosis of colorectal adenocarcinoma.
Progressed on or intolerant of at least 2 prior cancer therapy regimens administered for metastatic disease.
Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥3 weeks before the start of study therapy.
Part 2 only: Presence of radiographically measurable disease (defined as the presence of ≥1 lesion that measures ≥10 mm \[≥15 mm for lymph nodes\]). Measurable disease that was previously radiated is only permitted if progressing.
Agrees to undergo a pretreatment and a post-treatment biopsy.
Female subjects of childbearing potential must not be pregnant or breastfeeding
Willingness to use protocol-recommended methods of contraception or to abstain from heterosexual intercourse from start of therapy until at lest 30 days after the last dose of study therapy
Life expectancy of ≥3 months.
You may not be if
History of another malignancy except for adequately treated local basal cell or squamous cell carcinoma of the skin; in situ cervical or breast carcinoma; adequately treated, papillary, noninvasive bladder cancer; other adequately treated Stage 1 or 2 cancers currently in complete remission, or any other cancer that has been in complete remission for ≥2 years.
Known symptomatic brain metastases requiring ≥10 mg/day of prednisolone (or its equivalent).
Significant cardiovascular disease.
Significant screening ECG abnormalities.
Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent.
Known history of colitis, inflammatory bowel disease, pneumonitis, or pulmonary fibrosis.
Ongoing risk for bleeding due to active peptic ulcer disease or bleeding diathesis.
Evidence of an ongoing systemic bacterial, fungal, or viral infection.
Any condition that may impact the subject's ability to swallow oral medications.
Major surgery within 4 weeks before the start of study therapy.
Prior solid organ or bone marrow progenitor cell transplantation.
Prior therapy with any known inhibitor of MNK-1 or MNK-2.
Prior therapy with any of the following: PD-1, PD-L1, CTLA4 antibody, or any other drug targeting T cell checkpoint pathways.
Prior high dose chemotherapy requiring stem cell rescue.
Intolerance to or prior severe (≥Grade 3) allergic or anaphylactic reaction to infused antibodies or infused therapeutic proteins.
Vaccination within 4 weeks of the first dose of avelumab and while on study.
Ongoing immunosuppressive therapy.
Use of a strong inhibitor or inducer of cytochrome P450 3A4 (CYP3A4) within 7 days prior to the start of study therapy or expected requirement for use of a strong CYP3A4 inhibitor or inducer during study therapy.
Previously received investigational product in a clinical trial within 30 days or within 5 elimination half lives (whichever is longer) prior to the start of study therapy, or is planning to take part in another clinical trial while participating in this study.
Has any illness, medical condition, organ system dysfunction, or social situation, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a subject's ability to sign informed consent, adversely affect the subject's ability to cooperate and participate in the study, or compromise the interpretation of study results
Clareo Health | A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
